The recommended dose of ELIQUIS® is 5 mg taken orally twice daily (BD) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).1
Adapted from reference 1.
If a dose is missed, the patient should take ELIQUIS® as soon as they remember, and then continue to follow the regular dosing schedule.
For full information on dosing guidance, please visit SmPC.
The recommended dose of ELIQUIS® is 2.5 mg taken orally twice daily in patients with NVAF and at least two of the following characteristics: age ≥ 80 years, body weight ≤ 60 kg, or serum creatinine ≥1.5 mg/dl (133 micromole/l).1
Adapted from reference 1